Sandoz, the global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration (FDA) has approved Enzeevu™ (aflibercept-abzv) 2 mg...
Sandoz, a global leader in generic and biosimilar medicines, announced that it has submitted a Marketing Authorization Application for a proposed biosimilar trastuzumab (150...
